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Aspirin enhances platelet-derived growth 
factor-induced vascular smooth muscle 
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Russ Harvey,  MD,  Carl E. Bredenberg, MD,  Leslie Couper,  BS, and 
Jonathan H immel farb ,  MD,  Portland, Me. 
Purpose: Aspirin is frequently used after vascular econstruction to pharmacologically 
prevent graft occlusion and to suppress the development of myointimal hyperplasia in 
vascular surgery, but its efficacy is controversial. The purpose of this study was to examine 
the direct effects of aspirin on platelet-derived growth factor (PDGF)-induced vascular 
smooth muscle cell (SMC) proliferation. 
Methods: Human aortic SMCs were grown to confluence in 96 well plates. 3 x 10 -5 
mol /L  aspirin was added 24 hours previously and PDGF 10 ng/ml  at the beginning of 
each experiment. Cell proliferation at 48 hours was determined using tritiated thymidine 
uptake. Supernatant 12-L-hydroxy 5,8,10,14-eicosatetraenoic ac d (12-HETE) and 
prostaglandin E z (PGE2) were measured by competitive enzyme immunoassay. 
Results: Aspirin did not change vascular SMC proliferation rates relative to controls 
(4665 _ 181 counts per minute [CPM] vs 4749 ± 155 CPM). However, aspirin 
pretreatment of PDGF-stimulated vascular SMCs increased proliferation (9408 ± 237 
CPM vs 7283 ± 283 CPM; p < 0.001). 5,8,10,14-eicosatriynoic acid, a 12-1ipoxygenase 
inhibitor, decreased basal (2037 ± 181 CPM vs 2306 ± 158 CPM; p < 0.05) and 
PDGF-stimulated vascular SMC proliferation (4909 ± 1089 CPM vs 4310 ± 1022 
CPM; p < 0.001). Aspirin increased supernatant 12-HETE levels and decreased PGE 2 
levels in both basal and PDGF-stimulated cell cultures. 
Conclusions: Aspirin enhances PDGF-stimulated vascular SMC proliferation. The effects 
of aspirin on vascular SMC proliferation may be mediated by changes in vascular SMC 
arachidonic acid metabolism. (J Vasc Surg 1997;25:689-95.) 
Graft failure after arterial reconstruction or he- 
modialysis access urgery continues to result in con- 
siderable morbidity and mortality rates. It has been 
estimated that approximately 50% of all failures in 
arterial surgical reconstruction and more than 67% of 
hemodialysis graft failures are caused by an exuberant 
hyperplastic intimal response of the vascular wall, 
frequently referred to as myointimal or neointimal 
hyperplasia. 1-3 
To explain the development of  myointimal hy- 
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perplasia, which shares common characteristics with 
atherosclerosis, Russell Ross and others have formu- 
lated a "response to injuq'" hypothesis. 4 In this hy- 
pothesis, aprominent role is given to the secretion of 
platelet-derived growth factor (PDGF) by platelets 
adherent to the subendothelium. 4,s PDGF has been 
demonstrated both to increase SMC proliferation as 
well as to promote migration of the SMCs from 
media to intima. ~ Administration of PDGF increases 
myointimal hyperplasia formation, 6 whereas anti- 
body to PDGF reduces myointimal hyperplasia fter 
angioplasty in animal models. 7
Because of the postulated role of platelet activa- 
tion and secretion of PDGF, many clinical trials have 
fbcused on the use of  platelet inhibitors to prevent 
the development of myointimal hyperplasia. The 
drug most frequently used clinically in an attempt to 
pharmacologically suppress the development ofmyo- 
intimal hyperplasia has been acetylsalicylic acid (aspi- 
rin). Aspirin inhibits platelet aggregation by irrevers- 
ibly acetylating the enzyme cyclooxygenase, which, 
in platelets, catalyzes the formation of thromboxane 
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Fig. 1. Effects of aspirin on PDGF-stimulated VSMC 
proliferation. *p < 0.001 compared with control values; 
**p < 0.001 compared with PDGF stimulation alone; n = 
5 experiments. 
A 2 from arachidonic acid. 8 Aspirin has been shown to 
be effective in improving early graft patency 9 but not 
late graft patency ~° after coronary artery bypass graft- 
ing. Combined antiplatelet therapy with aspirin and 
dipyridamole is effective in increasing early patency 
rates in most ~1-~4 but not all ~5,~6 studies ofperiphcral 
vascular occlusive disease. However, the role of  aspi- 
rin alone in decreasing the incidence of intimal hy- 
perplasia nd late graft occlusion is controversial, and 
most experimental studies have demonstrated little, 
if any, benefit. ~7 22 
In addition to its effects on platelets, aspirin has 
direct affects on eicosanoid metabolism in vascular 
SMCs (VSMCs) that are important for cell stimula- 
tion and proliferation. Recent evidence has sug- 
gested that prostaglandin E2, the major cyclooxyge- 
nase-derived product ofarachidonic acid metabolism 
in VSMCs,  23 can suppress VSMC activation and pro- 
liferation. 23-26 On the other hand, 12-L-hydroxy 
5,8,10,14-eicosatetraenoic acid (12-HETE), the 
major lipoxygenase product of arachidonic acid me- 
tabolism in VSMCs,  27 is an important intracellular 
messenger and mitogen during VSMC activa- 
tion. 27-a4 Thus the alternate pathways of arachidonic 
acid metabolism in VSMC have end products with 
opposite ffects on the major component ofmyointi- 
mal hyperplasia, VSMC proliferation. 
On the basis of the postulated role of PDGF in 
the development of  atherosclerosis and intimal hy- 
perplasia, we have investigated the effect of aspirin on 
PDGF-induced VSMC proliferation. We hypothe- 
sized that the use of aspirin, by inhibiting cyclooxy- 
genase and stimulating lipoxygenase pathways, 
would shift the balance of eicosanoid metabolism to 
favor VSMC proliferation. 
METHODS 
Materials. Human aortic SMCs (HASMC) and 
smooth muscle basal media (SmBM) were purchased 
from Clonetics, Inc. (San Diego, Calif.). In all exper- 
iments, HASMC were maintained in SmBM, used 
between passages four through eight, and seeded at a 
density of 3.2 × 103 cells per well. PDGF-AB was 
purchased from Fisher Scientific (Medford, Mass.). 
Aspirin was purchased from Sigma Chemicals (St. 
Louis, Mo.). 5,8,10,14-eicosatetraenoic acid (ETI), 
a 12-1ipoxygenase inhibitor, was purchased from 
Calbiochem Biochemicals (San Diego, Calif.). Pros- 
taglandin E 2 (PGE2) and 12-HETE enzyme-linke d 
immunosorbent assay kits were purchased from Per- 
septive Diagnostics (Cambridge, Mass.). 
Trit iated thymidine assay. HASMC were 
seeded in 96 well plates (Coming Costar Corp., 
Oneonta, N.Y.) in SmBM containing 5% fetal bovine 
serum, 1% L-glutamine and 1% antibiotic/antimy- 
cotic solution. A 3.6 × 10 -2 mol /L  stock solution of  
aspirin was prepared in ethanol. The aspirin was 
added at a final concentration of 3 × 10 -2 mol /L  in 
SmBM with 5% fetal bovine serum and added to each 
appropriate well 24 hours before the start of the 
experiment. This dose of aspirin was chosen because 
it approximates the biologic effects of  a dose of 325 
mg per day in vivo 3s and because it has been used in 
previous in vitro studies with VSMCs. a6 PDGF was 
diluted in media, and 10 ng/ml  were added to ap- 
propriate wells at the beginning of each experiment. 
Seeded plates containing HASMC grown to near 
confluence were incubated in a 5% CO2 incubator at 
37 ° C during the experiments. The cells were incu- 
bated with tritiated thymidine (luCi per well) for 24 
hours before harvest. At 48 hours the cells were 
washed with phosphate-buffered saline solution and 
incubated with trypsin for 10 minutes. A Scatron cell 
harvester (Sterling, Va.) was used to capture DNA 
residue on filter discs. The filter discs were placed in a 
scintillation vial with scintillation fluid and counted 
on a Beta counter. The data are displayed as counts 
per minute and reflect new DNA synthesis and cellu- 
lar proliferation. 
PGE 2 and 12-HETE assays. HASMC were 
seeded in 96 well plates and grown to near conflu- 
ence. Twenty-four hours before experimentation, as-
pirin (3 × 10 -s mol /L)  was added. PDGF and aspi- 
rin were added at the beginning of the experiment. 
Supernatants were collected from the cells at 6 hours 
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after addition of PDGF for 12-HETE assays and at 
24 hours for PGE 2 assays and frozen at -70 ° C until 
assayed. PGE2 and 12-HETE concentrations were 
measured by competitive enzyme immunoassay 
methods. 12-HETE and PGE 2 concentrations were 
calculated on the basis of internal standard curves run 
with each assay. 
Statistical analysis. Changes in VSMC prolifer- 
ation, 12-HETE levels, and PGE 2 levels between 
experimental groups were analyzed using both 
paired t tests and multivariate regression analysis. 
The reported p values are based on t tests for the 
difference in means of  the two conditions in each 
experiment. All results are reported as mean _+ stan- 
dard error of the mean. Each experiment represents 
analysis of at least 12 data points per experimental 
condition. 
RESULTS 
Aspirin and SMC proliferation. Pretreatment 
of VSMC with 3 × 10 -5 mol /L  aspirin did not 
change basal proliferation rates relative to controls 
(4665 _ 181 counts per minute [CPM] vs 4749 _+ 
155 CPM; p = NS; Fig. 1). The addition of PDGF 
10 ng/ml  resulted in an increase in VSMC prolifera- 
tion above control values (7283 + 283 CPM vs 
4749 + 155 CPM; p < 0.001), as expected. Pre- 
treatment with aspirin significantly augmented the 
proliferate response of VSMC to PDGF (9408 + 
237 CPM) compared with PDGF alone or with con- 
trol cultures (p < 0.001 in both cases). 
Aspirin and supernatant 12-HETE levels. 
The addition of PDGF to VSMC did not result in 
increased concentration f 12-HETE compared with 
controls (6.99 + 0.63 ng/ml  vs 5.90 + 0.75 ng/ml;  
p = 0.27; Fig. 2). However, aspirin pretreatment of
VSMC increased supernatant 12-HETE concentra- 
tion after PDGF stimulation (9.62 _+ 0.73 ng/ml  vs 
6.99 +- 0.63 ng/ml;  p < 0.05) or compared with 
controls without PDGF stimulation (9.62 + 0.73 
ng/ml  vs 5.90 + 0.75; p < 0.01). There was also a 
trend toward increased 12-HETE supernatant con- 
centration with aspirin pretreatment and PDGF 
stimulation compared with PDGF stimulation alone 
(p = 0.09). The increase in 12-HETE levels indicates 
that aspirin pretreatment has increased PDGF-stim- 
ulated metabolism of arachidonic acid via lipoxygen- 
ase pathways. 
Aspirin and supernatant prostaglandin E2 lev- 
els. In comparison with control cultures, the pre- 
treatment of VSMC with 3 × 10 s mo l /L  aspirin 
decreased supernatant PGE 2 levels (2901 _+ 776 
pg/ml  vs 7296 + 1690 pg/ml;  p < 0.01; Fig. 3). In 
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Fig. 2. Effects of aspirin on VSMC culture 12-HETE 
levels. *p < 0.01 vs normal controls; **p < 0.05 vs PDGF 
alone; n = 8 experiments. 
PDGF-stimulated VSMC cultures, pretreatment 
with aspirin similarly decreased supernatant PGE 2 
concentration (3296 +_ 826 pg/ml  vs 8390 - 2231 
pg/ml;  p < 0.001). This confirms that aspirin re- 
duces metabolism of arachidonic acid via the cyclo- 
oxTgenase pathway in SMCs under these experimen- 
tal conditions, either in the presence or absence of 
PDGF. 
ETI and SMC proliferation. To determine 
whether PDGF-induced VSMC proliferation is de- 
pendent on endogenous 12-1ipoxygenase timula- 
tion, VSMC were pretreated with 10 Ixmolar ETI, a 
known inhibitor of 12-1ipo~,genase. Pretreatment 
resulted in basal proliferation rates that were de- 
creased relative to controls (2037 +_ 181 CPM vs 
2306 --- 158 CPM; p < 0.05; Fig. 4). Note that in 
comparison with Fig. 1, tritiated thymidine counts 
per minute were lower in control groups, likely re- 
flecting differences in VSMC confluence and passage 
number in these experiments. As expected, the addi- 
tion of PDGF resulted in an increase in VSMC pro- 
liferation above the control levels (4909 -+ 1089 
CPM with PDGF vs 2306 _+ 158 CPM without 
PDGF; p ~ 0.001). Pretreatment ofVSMC with ETI 
attenuated PDGF-induced VSMC proliferation 
(4310 -+ 1022 CPM vs 4909 +__ 1089 CPM; p < 
0.001), thereby demonstrating that 12-1ipoxygenase 
products contribute to PDGF-induced VSMC pro- 
liferation. 
DISCUSSION 
We have demonstrated that pretreatment of cul- 
tured human aortic SMCs with aspirin augments 
JOURNAL OF VASCULAR SURGERY 
692 Ham, ey et al. April 1997 
10000 
u~ 
 6ooo 
. j  
2OOO 
0 
Controls ASA PDGF ASA+PDGF 
Fig. 3. Effects of aspirin on VSMC supernatant PGE 2 
levels. *p < 0.01 vs control or PDGF stimulation; n = 5 
experiments. 
their proliferative response to PDGF. The mecha- 
nism by which aspirin augments the proliferative 
effect of PDGF may result from opposing effects of 
aspirin on the two alternative metabolic pathways of 
arachidonic acid in VSMCs. Binding of PDGF to its 
cell surface receptor in VSMCs causes a rapid phos- 
pholipase A2-mediated release of arachidonic acid 
from plasma membrane phospholipidsS -4° In the 
presence of a cyclooxygenase inhibitor such as aspi- 
rin, release of arachidonic acid leads to increased 
12-HETE production, as 12-HETE is the principal 
end product of the lipoxygenasc pathway of arachi- 
donic acid metabolism in VSMCs. In concordance 
with this, we have demonstrated that aspirin-we- 
treated VSMCs produced more 12-HETE and less 
PGE 2 after PDGF stimulation. 
Several studies have suggested that 12-HETE is 
an important second messenger in the stimulation of 
SMC proliferation. Activation of the 12-1ipoxygen- 
ase enzyme in VSMCs has been demonstrated in 
response to PDGF, angiotensin II, glucose, and ag- 
ing.27 34,41 The effects of 12-1ipoxygenase activation 
on cellular proliferation appeared to be mediated via 
activation of protein kinase C and by increasing intra- 
cellular calcium concentrations. 3°,33,42 Nakao and 
colleagues 27have previously reported that treatment 
of VSMCs with PDGF increased the endogenous 
production of 12-HETE by 26% to 46% compared 
with control evels. In this study we observed an 18% 
increase in supernatant 12-HETE levels after PDGF 
stimulation, which, however, was not statistically sig- 
nificant. Nakao ct al. measured 12-HETE levels in 
SMC homogenates, whereas we measured superna- 
tant levels of 12-HETE, which may account for the 
greater effect of aspirin on 12-HETE production in 
the earlier study. In our study aspirin pretreatment of 
PDGF-stimulated cells increased 12-HETE levels by 
38% compared with PDGF stimulation alone and by 
60% compared with control cultures, both of which 
were statistically significant. These results indicate 
that the effects of PDGF, which liberates plasma 
membrane arachidonic acid, and aspirin, which af- 
fects arachidonic acid synthetic pathways, are syner- 
gistic in their affects on both 12-HETE production 
and VSMC proliferation. 
The importance of 12-lipoxygenase products in 
VSMC activation has also been confirmed in experi- 
ments with lipoxygenase inhibitors. Previous tudies 
have used nordihydroguiaretic acid or baicalein as 
lipoxygenase pathway inhibitors and demonstrated 
suppression of aortic SMC growth .  42-4s Because 
these lipoxygenase inhibitors are relatively nonspe- 
cific, we chose to use ETI as a 12-1ipoxygenase inhib- 
itor. 46'47 Our  results demonstrated that ETI is able to 
partially inhibit the VSMC proliferative response to 
PDGF, either with or without aspirin pretreatment. 
The lack of a more complete inhibition of VSMC 
growth with ETI likely reflects both the importance 
of non-lipoxygenase-mediated proliferation as well 
as a lack of complete fficacy of ETI as a 12-1ipoxy- 
genase inhibitor. 
The other major pharmacologic effect of aspirin 
in these experiments i  to decrease cyclooxygenase 
products of arachidonic acid metabolism. Prosta- 
glandin E 2 and prostacyclin are inhibitors of VSMC 
proliferation, whereas thromboxane A 2 stimulates 
VSMC growth. 23,25,26 Because the major product of 
endogenous arachidonic acid metabolism is PGE2, 
the use of aspirin in these experiments increases 
VSMC proliferation. It should be noted that in vivo, 
where aspirin is also affecting platelet production of 
thromboxane and endothelial production of prosta- 
cyclin, in addition to direct effects on the vascular 
smooth musculature, the effects of aspirin are likely 
to be pharmacologically complex. 
Because aspirin has different sensitivity in vivo for 
inhibition of platelet, endothelial, and VSMC eico- 
sanoid formation, a continuing debate has ensued 
about what dose of aspirin is most efficacious as an 
antithrombotic agent. 8Whether there are significant 
clinical benefits to "prostacyclin-sparing" aspirin 
dosing that inhibit platelet but not endothelial eico- 
sanoid production remains controversial. As an ex- 
ample, the Dutch TIA Trial that compared 30 mg 
and 280 mg of aspirin in more than 3000 patients 
showed the lower dose of aspirin to be slightly more 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 4 Harvey et al. 693 
effective, but the differences were not statistically 
significant. It is clear that higher aspirin doses (e.g., 
900 to 1500 mg per day) lack increased efficacy as an 
antithrombotic agent compared with standard oses, 
although igher doses may have additional antirheu- 
matic effects that are not mediated via prostaglandin 
pathways, as
In this study, we chose to use 3 × 10 5 mol /L  
aspirin in culture medium to be equivalent to the 
standard ose of aspirin (325 mg) 30 minutes after 
administration i  vivo. Thus the results obtained in 
these in vitro studies hould be generalizable to pa- 
tients who take a standard 325 mg/day dose of 
aspirin? 5,36 Of note, a recent study has demonstrated 
that aspirin at very high concentrations can inhibit 
VSMC proliferation in culture. 49 The relevance of 
these investigators' findings to our data or to patients 
taking aspirin are unclear because of the aspirin dose 
chosen. 
Despite the frequent clinical use of aspirin after 
vascular surgery, the results of clinical trials evaluat- 
ing its efficacy in preventing myointimal hyperplasia 
have generally been disappointing. Clagett et al. s° 
have recently published an evaluation of studies of 
antithrombotic therapy in peripheral arterial occlu- 
sive disease. In human beings, there appears to be no 
clear benefit of using antiplatelet agents in the pre- 
vention of intimal hyperplasia nd late graft occlu- 
sion, although there is a benefit in early graft patency 
rates. Similarly, there have been a number of large 
clinical studies that have evaluated the efficacy of 
using antiplatelet therapy in patients undergoing sa- 
phenous vein coronary artery bypass grafts, with 
mixed results. Meta-analysis has demonstrated bene- 
fit in reducing early graft occlusion 9 but no reduction 
in intimal hyperplasia or late graft occlusion with 
antiplatelet agents. 1° Thus the timing of beneficial 
effects of aspirin in improving patency rates in arterial 
reconstructions suggests that benefit is related to its 
antithrombotic effects and not to any reduction in 
myointimal hyperplasia. 
An analysis of the effects of aspirin on the patency 
of vascular access in hemodialysis patients also has 
not demonstrated fficacy in preventing myointimal 
hyperplasia. Recently, the results of a randomized, 
double-blinded, placebo-controlled trial ofantiplate- 
let agents to prevent polytetrafluoroethylene graft 
thrombosis in hemodialysis patients has been pub- 
lished. 51 Surprisingly, patients in the aspirin-alone 
arm had 1.99 times the relative risk of thrombosis as 
patients in the placebo arm, with the difference in the 
aspirin-treated group manifesting after more than 6 
months, suggesting the involvement of myointimal 
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Fig. 4. Effects of ETI on PDGF-stimulated VSMC prolif- 
eration. *p < 0.05 compared with control values; **p < 
0.001 compared with PDGF stimulation alone; n = 4 
experiments. 
hyperplasia. Thus with polytetrafluoroethylene grafts 
for hemodialysis access, as well as for peripheral arte- 
rial occlusive disease and cardiopulmonary bypass 
grafting, the results of studies using aspirin in an 
attempt to improve graft patency and to reduce myo- 
intimal hyperplasia have been disappointing. 
In addition to the direct effects of aspirin on 
vascular smooth muscle proliferation that we have 
demonstrated, there are other potential explanations 
for its lack of observed efficacy in the prevention of 
myointimal hyperplasia development. Recent studies 
suggest hat aspirin does not inhibit the interaction 
of platelets with monocytes or polymorphonuclear 
cells, which are postulated to play a role in myointi- 
mal hyperplasia development, s2 Aspirin also de- 
creases prostacyclin and 13-hydroxyoctadecadenoic 
acid production by the endothelium, making the 
vessel wall more adhesive to plateletsY All of these 
aspirin-mediated ffects may be additive or synergis- 
tic in vivo with the direct effects of aspirin on the 
VSMC that we have observed. 
CONCLUSION 
We have demonstrated a irect effect of aspirin in 
increasing PDGF-induced SMC proliferation. This 
effect may be mediated by shunting arachidonic acid 
released from VSMC plasma membrane phospholip- 
ids into formation of 12-HETE, a known VSMC 
mitogen, and away from PGE 2, a known inhibitor of 
VSMC stimulation. The experimental observations 
that aspirin increases the proliferative ffect of PDGF 
on cultured VSMCs call into question the rationale 
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for clinically using aspirin to prevent myointimal hy- 
perplasia after arterial reconstruction or dialysis ac- 
cess procedures. 
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